OliX Pharmaceuticals to Present at SMi 13th Annual RNA Therapeutics Conference
February 07, 2022 08:30 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Feb. 07, 2022 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
OliX Pharmaceuticals to Participate in BIO Partnering at JPM and Biotech Showcase 2022 Conferences
January 03, 2022 08:30 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea., Jan. 03, 2022 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
OliX Pharmaceuticals Subsidiary mCureX Strengthens Scientific Advisory Board with Appointment of Nucleic Acid Therapeutics and Immunology Specialist Dr. Gunther Hartmann
November 30, 2021 08:00 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Nov. 30, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the appointment of Dr. Gunther...
OliX Pharmaceuticals to Conduct One-on-One Meetings at BIO-Europe Digital 2021 Conference
October 21, 2021 12:00 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Oct. 21, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
OliX Pharmaceuticals Enters Agreement with Pharmaron to Advance Non-clinical Toxicology Testing for Hepatitis B Candidate OLX703A
October 20, 2021 08:30 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Oct. 20, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has selected...
Hansoh Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement to Develop and Commercialize siRNA Therapeutics in Greater China
October 12, 2021 07:00 ET
|
OliX Pharmaceuticals; Hansoh Pharmaceutical Group Co, Ltd
Companies to focus on cardiovascular, metabolic, and other indicationsOliX will receive initial upfront payment of $6.5 million with up to $450 million plus royalties SHANGHAI, China and SUWON,...
OliX Pharmaceuticals to Present at 2021 Oligonucleotide Therapeutics Society Virtual Conference
September 24, 2021 08:30 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Sept. 24, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company will present new...
OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Investigational Hair Loss Therapeutic, OLX104C
August 12, 2021 09:00 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Aug. 12, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has received a...
OliX Pharmaceuticals Announces Results from Preclinical Study of NASH Therapeutic Candidate
August 04, 2021 09:00 ET
|
OliX Pharmaceuticals
- OLX702A reversed liver tissue damage in mouse model of NASH - Results and additional pipeline updates across hair loss, AMD and HBV programs presented at 48th KAST International Symposium -...
OliX Pharmaceuticals to Present at 2021 RNAi-Based Therapeutics Summit
June 14, 2021 10:00 ET
|
OliX Pharmaceuticals
SUWON, Republic of Korea, June 14, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that June Hyun Park, Ph.D.,...